Our findings suggest that liraglutide, through its targeting of GLP1Rs, affects the expression of ILK-related PI3K/AKT/PTEN, ultimately mitigating diabetic cardiomyopathy by regulating these signaling pathways. This evidence concerns the gene AKT1 and diabetic cardiomyopathy.